Filana Therapeutics, Inc. Diluted Shares Outstanding (Weighted Average)
Filana Therapeutics, Inc. (FLNA) reported Diluted Shares Outstanding (Weighted Average) of 48.30 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-03-12
- Filana Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 48.31M shares, a 0.41% increase year-over-year.
- Filana Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 48.31M shares, a 0.69% increase year-over-year.
- Filana Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-06-30 was 48.31M shares, a 4.56% increase year-over-year.
- Filana Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-03-31 was 48.26M shares, a 9.43% increase year-over-year.
- Filana Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2025 was 48.30M shares, a 3.63% increase from fiscal 2024.
- Filana Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2024 was 46.60M shares, a 11.14% increase from fiscal 2023.
- Filana Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2023 was 41.93M shares, a 4.30% increase from fiscal 2022.
- Filana Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2022 was 40.20M shares.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|
| 2025-12-31 | 48.31M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 48.31M shares derived: average of 2 quarters · filed 2026-03-12 | 48.31M shares derived: average of 3 quarters · filed 2026-03-12 | 48.30M shares 10-K · filed 2026-03-12 |
| 2025-09-30 | 48.31M shares 10-Q · filed 2025-11-12 | 48.31M shares derived: average of 2 quarters · filed 2025-11-12 | 48.29M shares 10-Q · filed 2025-11-12 | 48.25M shares derived: average of 4 quarters · filed 2026-03-12 |
| 2025-06-30 | 48.31M shares 10-Q · filed 2025-08-14 | 48.28M shares 10-Q · filed 2025-08-14 | 48.23M shares derived: average of 3 quarters · filed 2026-03-12 | 48.16M shares derived: average of 4 quarters · filed 2026-03-12 |
| 2025-03-31 | 48.26M shares 10-Q · filed 2025-05-08 | 48.19M shares derived: average of 2 quarters · filed 2026-03-12 | 48.12M shares derived: average of 3 quarters · filed 2026-03-12 | 47.64M shares derived: average of 4 quarters · filed 2026-03-12 |
| 2024-12-31 | 48.11M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 48.04M shares derived: average of 2 quarters · filed 2026-03-12 | 47.43M shares derived: average of 3 quarters · filed 2026-03-12 | 46.60M shares 10-K · filed 2026-03-12 |
| 2024-09-30 | 47.98M shares 10-Q · filed 2025-11-12 | 47.09M shares derived: average of 2 quarters · filed 2025-11-12 | 46.10M shares 10-Q · filed 2025-11-12 | 45.12M shares derived: average of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | 46.20M shares 10-Q · filed 2025-08-14 | 45.15M shares 10-Q · filed 2025-08-14 | 44.17M shares derived: average of 3 quarters · filed 2026-03-12 | 43.62M shares derived: average of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | 44.10M shares 10-Q · filed 2025-05-08 | 43.15M shares derived: average of 2 quarters · filed 2026-03-12 | 42.77M shares derived: average of 3 quarters · filed 2026-03-12 | 42.52M shares derived: average of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | 42.19M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 42.10M shares derived: average of 2 quarters · filed 2026-03-12 | 42.00M shares derived: average of 3 quarters · filed 2026-03-12 | 41.93M shares 10-K · filed 2026-03-12 |
| 2023-09-30 | 42.00M shares 10-Q · filed 2024-11-07 | 41.90M shares derived: average of 2 quarters · filed 2024-11-07 | 41.84M shares 10-Q · filed 2024-11-07 | |
| 2023-06-30 | 41.79M shares 10-Q · filed 2024-08-08 | 41.77M shares 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | 41.74M shares 10-Q · filed 2024-05-10 | |||
| 2022-12-31 | 40.20M shares 10-K · filed 2025-03-03 | |||
| 2022-06-30 | 40.02M shares 10-Q · filed 2023-08-03 | 39.99M shares 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | 39.96M shares 10-Q · filed 2023-05-01 | |||
| 2015-12-31 | 45.76M shares 10-K · filed 2016-03-03 | |||
| 2014-12-31 | 45.27M shares 10-K · filed 2016-03-03 | |||
| 2013-12-31 | 45.21M shares 10-K · filed 2016-03-03 | |||
| 2013-03-31 | 44.93M shares 10-Q · filed 2013-04-24 | |||
| 2012-12-31 | 44.75M shares 10-K · filed 2015-02-18 | |||
| 2012-03-31 | 44.76M shares 10-Q · filed 2013-04-24 | |||
| 2011-12-31 | 44.16M shares 10-K · filed 2014-02-05 | |||
| 2011-03-31 | 43.12M shares 10-Q · filed 2012-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |